Which company develops and produces Rituximab?

Rituximab is produced by Roche Pharmaceuticals of Switzerland. It was approved for medical use in 1997 and began sales in China in 2000. Rituximab injection products are used alone or in combination with other medicines to treat various types of non-Hodgkin lymphoma (NHL) in adults. Rituximab injection products are also used with other drugs to treat chronic lymphocytic leukemia in adults. Rituximab injection is also used with methotrexate to treat rheumatoid arthritis in adults who have been treated with a drug called a tumor necrosis factor (TNF) inhibitor. Rituximab injectable products are also used in adults and children 2 years and older, along with other drugs to treat granulomatosis with polyangiitis and microscopic polyangiitis, a disease in which the body attacks its own veins and other blood vessels, causing damage to organs such as the heart and lungs. Rituximab injection is used to treat pemphigus vulgaris.

Rituximab injectable products belong to a class of drugs called monoclonal antibodies, which treat various types of non-Hodgkin lymphoma and CLL by killing cancer cells. Certain injectable rituximab products also treat rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris by blocking the activity of parts of the immune system that can damage joints, veins, and other blood vessels. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.